{"id":647,"date":"2011-04-05T22:27:15","date_gmt":"2011-04-05T21:27:15","guid":{"rendered":"https:\/\/blogs.bmj.com\/heart-journalscan\/?p=647"},"modified":"2015-11-12T15:33:57","modified_gmt":"2015-11-12T14:33:57","slug":"2-year-resolute-data-emphasis-need-for-secondary-prevention","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/","title":{"rendered":"2-year RESOLUTE data emphasise need for secondary prevention"},"content":{"rendered":"<p>The RESOLUTE All Comers trial showed that the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus eluting stent in terms of target lesion failure (revascularisation, myocardial infarction, or cardiac death). \u00a0However, long-term follow-up data from drug-eluting stent trials are generally scarce. \u00a0Silber et al. report the 2-year clinical outcomes from the original RESOLUTE trial.<!--more--><\/p>\n<p>All patients in the study had at least one coronary lesion between 2.25 and 4.0mm in diameter causing more than 50% stenosis. \u00a0There were no restrictions as to the number of stents implanted, nor the the number of vessels or lesions treated. \u00a0Safety and efficacy outcomes examined at two years included death, myocardial infarction, revascularisation and stent-related composite outcomes.<\/p>\n<p>1140 patients were assigned to Resolute and 1152 to Xience stents, of which 1121 and 1128, respectively, completed 2-year follow-up. \u00a0No difference was noted between patient-related outcomes (death, MI, revascularisation, 20.6% vs 20.5%; p=0.958) and stent-related outcomes (11.2% vs 10.7%; p=0.736) in the two patient groups. \u00a0In additon, only three patients in each group had stent thrombosis after one year (very late stent thrombosis). \u00a0Therefore despite a low rate of problems with the stents themselves, many patients went on to have further cardiac events.<\/p>\n<p><strong>Conclusions:<\/strong><\/p>\n<p>At 2-year follow-up, no significant safety or efficacy differences existed between Resolute and Xience stents. \u00a0However, a high rate of recurrent events emphasises the need for effective secondary prevention in patients with established coronary disease.<\/p>\n<ul>\n<li>Silber S, Windecker SS, Vranckx P et al. \u00a0Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011. DOI:\u00a010.1016\/S0140-6736(11)60395-4<\/li>\n<\/ul>\n<p><figure id=\"attachment_648\" aria-describedby=\"caption-attachment-648\" style=\"width: 512px\" class=\"wp-caption alignnone\"><a href=\"https:\/\/blogs.bmj.com\/heart-journalscan\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/resolute\/\" rel=\"attachment wp-att-648\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-648\" src=\"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2011\/04\/RESOLUTE.jpg\" alt=\"\" width=\"512\" height=\"200\" \/><\/a><figcaption id=\"caption-attachment-648\" class=\"wp-caption-text\">Patient-related vs. stent-related outcomes in the RESOLUTE trial<\/figcaption><\/figure><!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The RESOLUTE All Comers trial showed that the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus eluting stent in terms of target lesion failure (revascularisation, myocardial infarction, or cardiac death). \u00a0However, long-term follow-up data from drug-eluting stent trials are generally scarce. \u00a0Silber et al. report the 2-year clinical outcomes from the original RESOLUTE [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":47,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[288],"tags":[485,524],"class_list":["post-647","post","type-post","status-publish","format-standard","hentry","category-molecular-cardiology","tag-drug-eluting-stents","tag-pci"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>2-year RESOLUTE data emphasise need for secondary prevention - Heart<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2-year RESOLUTE data emphasise need for secondary prevention - Heart\" \/>\n<meta property=\"og:description\" content=\"The RESOLUTE All Comers trial showed that the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus eluting stent in terms of target lesion failure (revascularisation, myocardial infarction, or cardiac death). \u00a0However, long-term follow-up data from drug-eluting stent trials are generally scarce. \u00a0Silber et al. report the 2-year clinical outcomes from the original RESOLUTE [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/\" \/>\n<meta property=\"og:site_name\" content=\"Heart\" \/>\n<meta property=\"article:published_time\" content=\"2011-04-05T21:27:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-11-12T14:33:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2011\/04\/RESOLUTE.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"2-year RESOLUTE data emphasise need for secondary prevention\",\"datePublished\":\"2011-04-05T21:27:15+00:00\",\"dateModified\":\"2015-11-12T14:33:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/\"},\"wordCount\":282,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2011\\\/04\\\/RESOLUTE.jpg\",\"keywords\":[\"drug-eluting stents\",\"PCI\"],\"articleSection\":[\"Molecular Cardiology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/\",\"name\":\"2-year RESOLUTE data emphasise need for secondary prevention - Heart\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2011\\\/04\\\/RESOLUTE.jpg\",\"datePublished\":\"2011-04-05T21:27:15+00:00\",\"dateModified\":\"2015-11-12T14:33:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2011\\\/04\\\/RESOLUTE.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart-journalscan\\\/files\\\/2011\\\/04\\\/RESOLUTE.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/2011\\\/04\\\/05\\\/2-year-resolute-data-emphasis-need-for-secondary-prevention\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2-year RESOLUTE data emphasise need for secondary prevention\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"name\":\"Heart\",\"description\":\"Highlighted articles from non-cardiological journals relevant to cardiology\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#organization\",\"name\":\"Heart\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/files\\\/2017\\\/11\\\/blog-logo-heart.png\",\"width\":145,\"height\":34,\"caption\":\"Heart\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/heart\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2-year RESOLUTE data emphasise need for secondary prevention - Heart","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/","og_locale":"en_US","og_type":"article","og_title":"2-year RESOLUTE data emphasise need for secondary prevention - Heart","og_description":"The RESOLUTE All Comers trial showed that the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus eluting stent in terms of target lesion failure (revascularisation, myocardial infarction, or cardiac death). \u00a0However, long-term follow-up data from drug-eluting stent trials are generally scarce. \u00a0Silber et al. report the 2-year clinical outcomes from the original RESOLUTE [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/","og_site_name":"Heart","article_published_time":"2011-04-05T21:27:15+00:00","article_modified_time":"2015-11-12T14:33:57+00:00","og_image":[{"url":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2011\/04\/RESOLUTE.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/"},"author":{"name":"","@id":""},"headline":"2-year RESOLUTE data emphasise need for secondary prevention","datePublished":"2011-04-05T21:27:15+00:00","dateModified":"2015-11-12T14:33:57+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/"},"wordCount":282,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2011\/04\/RESOLUTE.jpg","keywords":["drug-eluting stents","PCI"],"articleSection":["Molecular Cardiology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/","url":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/","name":"2-year RESOLUTE data emphasise need for secondary prevention - Heart","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/heart\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2011\/04\/RESOLUTE.jpg","datePublished":"2011-04-05T21:27:15+00:00","dateModified":"2015-11-12T14:33:57+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#primaryimage","url":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2011\/04\/RESOLUTE.jpg","contentUrl":"https:\/\/blogs.bmj.com\/heart-journalscan\/files\/2011\/04\/RESOLUTE.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/heart\/2011\/04\/05\/2-year-resolute-data-emphasis-need-for-secondary-prevention\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/heart\/"},{"@type":"ListItem","position":2,"name":"2-year RESOLUTE data emphasise need for secondary prevention"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/heart\/#website","url":"https:\/\/blogs.bmj.com\/heart\/","name":"Heart","description":"Highlighted articles from non-cardiological journals relevant to cardiology","publisher":{"@id":"https:\/\/blogs.bmj.com\/heart\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/heart\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/heart\/#organization","name":"Heart","url":"https:\/\/blogs.bmj.com\/heart\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","contentUrl":"https:\/\/blogs.bmj.com\/heart\/files\/2017\/11\/blog-logo-heart.png","width":145,"height":34,"caption":"Heart"},"image":{"@id":"https:\/\/blogs.bmj.com\/heart\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blogs.bmj.com\/heart\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/comments?post=647"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/posts\/647\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/media?parent=647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/categories?post=647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/heart\/wp-json\/wp\/v2\/tags?post=647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}